The reduction in the levels of plasma EV-TGFβ1 protein in AML patients who received chemotherapy is indicative of the favorable response to treatment and induction of long-term complete remission. Changes in EV-TGFβ1 levels in AML patients could be considered a prognostic and risk stratifying factor. The gene discussed is TGFB1; the disease is acute myeloid leukemia.